Cocrystal Pharma, Inc. (COCP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 5M 10M 15M FY11: 12.7M FY19: 6.6M FY20: 2M FY11 FY19 FY20

Gross Profit Annual

0 2.5M 5M 7.5M FY10: 6.8M FY11: 2.7M FY12: 7.2M FY10 FY11 FY12

Operating Income Annual

-120M -80M -40M 0 40M 80M 120M FY16: -105.8M FY17: -8.3M FY18: -62.9M FY19: -48.4M FY20: -9.6M FY21: -14.2M FY22: -38.8M FY23: -18.6M FY24: -17.9M FY25: -9M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Net Income Annual

-90M -60M -30M 0 30M 60M 90M FY16: -74.9M FY17: -613K FY18: -49M FY19: -48.2M FY20: -9.6M FY21: -14.2M FY22: -38.8M FY23: -18M FY24: -17.5M FY25: -8.8M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

0 150K 300K 450K FY12: 405.9K FY12

Operating Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY16: -14.7M FY17: -6.9M FY18: -8.3M FY19: -1.6M FY20: -9.8M FY21: -12.7M FY22: -21.4M FY23: -14.7M FY24: -16.5M FY25: -8.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY16: -14.7M FY17: -6.9M FY18: -8.3M FY19: -1.7M FY20: -10.1M FY21: -12.8M FY22: -21.5M FY23: -14.8M FY24: -16.5M FY25: -8.2M FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 9M 18M 27M FY15: 21M FY16: 23.5M FY17: 24.1M FY18: 28K FY19: 31.9K FY21: 7.4M FY22: 8.1M FY23: 9.7M FY24: 10.2M FY25: 11.3M FY15 FY16 FY17 FY18 FY19 FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q1 '12: -0.15 Q2 '12: -0.15 Q3 '12: -0.11 Q4 '12: -0.13 Q3 '16: -0.06 Q4 '16: -3.07 Q1 '17: -3.17 Q2 '17: -3.26 Q3 '17: -3.26 Q4 '17: 0.00 Q1 '18: 0.05 Q2 '18: 0.09 Q3 '18: 0.03 Q4 '18: -1.75 Q1 '19: -1.59 Q2 '19: -1.59 Q3 '19: -1.59 Q4 '19: -1.51 Q1 '20: -1.66 Q2 '20: -1.68 Q3 '20: -1.67 Q4 '20: -0.18 Q1 '21: -0.17 Q2 '21: -0.14 Q3 '22: -4.26 Q4 '22: -4.76 Q1 '23: -4.88 Q2 '23: -2.29 Q3 '23: -2.00 Q4 '23: -1.90 Q1 '24: -1.65 Q2 '24: -1.77 Q3 '24: -1.85 Q4 '24: -1.73 Q1 '25: -1.57 Q2 '25: -1.24 Q3 '25: -0.94 Q4 '25: -0.79 Q1 '26: -0.73 Q2 '26: -0.76 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.